Introduction Patients with rheumatoid arthritis (RA) are at an increased risk of malignancies
compared with the general population. This has raised concerns regarding these patients …

Monoclonal antibodies (mAbs) are now established as targeted therapies for malignancies,
transplant rejection, autoimmune and infectious diseases, as well as a range of new …

Over the past decade, an increasing number of observational studies have examined the
effectiveness or safety of treatments for rheumatoid arthritis. Unlike randomized controlled …

BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) are at risk for
certain malignancies. We aimed to determine the risk of melanoma and nonmelanoma skin …

Objectives This project was undertaken to assess the risk of malignancy in patients with
rheumatoid arthritis treated with tumour necrosis factor inhibitors (TNFi) in clinical practice …

Background Improved understanding of rheumatoid arthritis (RA) pathogenesis has led to
the development of new biologic treatments that target specific elements of RA inflammatory …

Rheumatoid arthritis (RA) is often characterized by the burden of swollen joints, pain, and
decreased physical function, but less understood are the many manifestations of additional …

Context Concerns exist regarding the potential development of malignancies in patients with
rheumatoid arthritis (RA) who are receiving biologic response modifiers (BRMs). Objective …

Introduction The risk of malignancies in patients with rheumatoid arthritis (RA) has raised
some concern, particularly with immunosuppressive approaches to disease management …

Objectives To review the evidence for the efficacy and safety of biological agents in patients
with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the …